Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients

Blood Pressure

Volumn 5, Issue 1, 1996, Pages 32-40

  Ruilope, Luis M ^a   Simpson, Roger L ^b   Toh, Jenny ^b   Arcuri, Karen E ^b   Goldberg, Allan I ^b   Sweet, Charles S ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiotensin II receptor antagonist; Blood pressure; Essential hypertension; Hydrochlorothiazide; Losartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; POTASSIUM; URIC ACID;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029915382     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059609062104     Document Type: Article

References (14)

1. Laragh JH. Historical perspective on renin system blockade in the treatment of hypertension. Am J Hypertens 1992; 5: 207S-8.
2. Smith RD, Chin AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992; 32: 135-65.
3. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan. A preliminary report. Am J Hypertens 1992; 5: 247S-51.
4. Tsunoda K, Abe K, Hagino T, Misawa S, Imai Y, Yoshinaga K. Hypotensive effect of losartan a nonpeptide angiotensin II receptor in essential Hypertension. Am J Hypertens 1993; 6: 28-32.
5. Wong PC, Price WA Jr., Chiu AT, Duncia JV, Carini DJ, Wexler RR et al. Nonpeptide angiotensin II receptor antagonists XI. Pharmacology of Exp. 3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211-17.
6. Timmermans PBMWM. Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991; 12: 55-62.
7. Burnier M, Centeno G, Grouzmann E, Walker P, Waeber B, Brunner HR. In vitro effects of DuP 753, a nonpeptide angiotensin II, on human plateiets and rat vascular smooth muscle cells. Am J Hypertens 1991: 4: 438-43.
8. Ménard J. Critical assessment of combination therapy development. Blood Pressure 1993; 2 (Suppl 1): 5-9.
9. Cappuccio FP, MacGregor GA. Combination therapy in hypertension. In: Laragh JH. Brenner BM. eds. Hypertension, pathophysioloay and management. New York; Raven Press. 1995: 2969-83.
10. Sassano P, Chatellier G, Billaud E, Corvol P, Menard J. Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled on enalapril alone. J Cardiovasc Pharmacol 1989; 13: 314-9.
11. Vidt DG for The Multiclinic Study Group. A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mud to moderate hypertension. J Hypertens 1984; 2 (Suppl 2): 81-8.
12. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new ansiotensin II receptor antagonist in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-5.
13. Dahlöf B, Hansson L, Acosta JH, Bolzano K, Fairhurst G, Ferreira C et al. Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients. Am J Hypertens 1988; 1: 38-41.
14. Andr̀en L, Weiner L, Svensson A, Hansson L. Enalapril with either a "very low" or "low" dose of hydrochlorothiazide is equally effective in essential hypertension: a double-blind trial in 100 hypertensive patients. J Hypertens 1983; 1 (Suppl 2): 384-6.